YOLFTbeta
Beijing Kawin Technology Share-holding Co Ltd

Beijing Kawin Technology Share-holding Co Ltd

688687 · SHG · Healthcare / Biotechnology

15.70CNY-0.31 (-1.94%)

Price History

Full chart

Market Stats

Previous Close16.01
Open16.01
Day Range15.63 – 16.11
52-Week Range14.61 – 29.37
Volume1.61M
Market Cap3.23B
P/E (TTM)378.20
Forward P/E0.00
EPS0.05
Dividend Yield1.32%
Beta0.49
50-Day Avg17.65
200-Day Avg19.62

About

Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. The company offers recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon alfacon-2 injection; and compound glycyrrhizin tablets, capsules, and injections; and pirfenidone tablets for mild to moderate idiopathic pulmonary fibrosis. It is also involved in contract manufacture organization/contract development and manufacturing organization; technology and biotechnology development and consulting; technology promotion and application; and wholesale of pharmaceutical. Beijing Kawin Technology Share-Holding Co., Ltd. was incorporated in 2008 and is based in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Desheng Zhou
  • Employees601
  • HeadquartersBuilding 3, No. 6, Rongjing East Street, Beijing, China, 100176, China
  • Websitehttps://www.kawin.com.cn

Leadership

  • Mr. Desheng ZhouPresident & Chairman of the Board · b. 1971
  • Ms. Huan WangExecutive VP & Director · b. 1979
  • Mr. Jifeng ShiVP, Chief Research Officer, Core Technical Personnel & Director · b. 1974
  • Ms. Shan LiuHead of Antibody Drug Development Department & Core Technical Personnel · b. 1988
  • Mr. Xiang LiManager of Information Strategy Research Department & Core Technical Personnel · b. 1983
  • Mr. Zhenqiang DuVice President · b. 1976
  • Mr. Lu YangDeputy GM of Beiyi Protein Drug R&D and Core Technical Personnel · b. 1983
  • Mr. Jian TangVice President · b. 1978
  • Ms. Xiao XuVice President · b. 1974
  • Ms. Hong Juan LiuChief Financial Officer · b. 1976

Financials

Income Statement

Currency: CNY2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-59.22M109.92M150.76M180.15M200.43M225.15M267.75M490.55M705.86M824.92M862.05M1.14B1.16B1.41B1.23B1.32B
Growth (%)--+85.61%+37.16%+19.50%+11.26%+12.33%+18.92%+83.21%+43.89%+16.87%+4.50%+32.75%+1.36%+21.73%-12.87%+7.35%
Cost of Revenue-21.60M45.97M56.36M67.45M70.04M71.29M72.27M78.86M99.08M106.03M114.92M143.73M157.47M233.20M223.42M235.68M
Gross Profit-37.62M63.95M94.40M112.71M130.39M153.86M195.48M411.69M606.78M718.90M747.14M1.00B1.00B1.18B1.01B1.09B
Gross Margin-63.52%58.18%62.62%62.56%65.06%68.34%73.01%83.92%85.96%87.15%86.67%87.44%86.42%83.48%81.84%82.16%
Operating Expense-29.50M46.77M63.30M96.32M111.85M143.69M172.40M383.86M557.57M651.55M658.39M870.03M896.02M1.01B813.84M1.02B
Operating Income-19.05K8.12M17.19M31.10M16.39M18.54M10.17M23.07M27.83M49.21M67.35M88.75M130.60M106.48M170.83M193.03M63.24M
Operating Margin-13.71%15.64%20.63%9.10%9.25%4.52%8.62%5.67%6.97%8.16%10.30%11.41%9.18%12.10%15.69%4.79%
EBITDA-19.05K12.80M24.31M40.77M22.21M38.62M32.62M47.95M51.29M71.26M89.88M121.02M158.73M135.13M185.26M220.58M63.24M
EBITDA Margin-21.61%22.12%27.04%12.33%19.27%14.49%17.91%10.45%10.10%10.90%14.04%13.87%11.65%13.12%17.93%4.79%
Net Income-6.91M15.94M29.69M18.19M17.06M12.09M23.93M26.83M44.85M53.56M75.57M107.29M83.41M116.52M142.37M29.63M
Net Income Margin-11.67%14.50%19.70%10.09%8.51%5.37%8.94%5.47%6.35%6.49%8.77%9.38%7.19%8.25%11.57%2.24%
R&D-----47.76M55.64M36.84M43.49M53.22M35.38M56.42M77.40M125.85M142.17M138.16M140.90M
R&D as % of Total Revenue-----23.83%24.71%13.76%8.87%7.54%4.29%6.55%6.76%10.85%10.07%11.23%10.67%
Interest Expense--198.78K868.59K3.12M5.53M7.83M4.71M1.41M137.58K128.09K165.42K176.50K1.10M952.39K1.68M2.87M
Interest Expense % of Total Revenue--0.18%0.58%1.73%2.76%3.48%1.76%0.29%0.02%0.02%0.02%0.02%0.09%0.07%0.14%0.22%

Balance Sheet

Currency: CNY2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets32.00M69.56M164.82M210.07M312.94M403.63M439.24M695.21M723.61M814.56M1.05B1.17B2.18B2.21B2.45B2.62B2.79B
Total Liabilities-30.65M71.98M87.53M149.01M182.89M199.51M149.38M111.24M159.69M280.67M318.56M490.27M527.93M663.01M735.33M1.05B
Total Equity32.00M38.91M92.84M122.53M157.71M214.95M227.35M532.77M609.45M655.42M772.15M847.72M1.68B1.68B1.75B1.84B1.71B
Cash9.90M10.64M33.48M61.88M76.59M107.58M39.71M189.95M245.51M255.62M358.24M419.64M1.16B726.38M853.63M902.83M833.97M
Total Debt--24.00M34.00M94.05M126.54M73.60M70.94M----3.42M15.62M53.42M245.62M-
Net Debt-9.90M-10.64M-9.48M-27.88M17.46M18.96M33.89M-119.00M-245.51M-255.62M-358.24M-419.64M-1.15B-710.76M-798.71M-657.22M-

Cash Flow

Currency: CNY2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow17.43M25.17M32.26M28.38M16.77M49.67M8.13M14.20M60.31M102.94M131.42M117.94M134.05M126.60M104.29M110.29M
Investing Cash Flow-16.68M-47.37M-4.73M-70.48M-54.63M-88.03M-108.33M-10.20M-50.40M-47.53M-78.51M-89.66M-493.56M-61.03M-176.92M-
Financing Cash Flow-45.03M877.83K56.81M68.30M-28.91M250.44M116.53M047.21M8.48M705.95M-76.37M8.92M84.54M-
Capital Expenditure16.68M47.37M4.77M74.68M61.99M93.16M77.03M56.39M50.66M49.06M41.56M43.98M75.02M154.68M266.76M134.02M
Free Cash Flow744.38K-22.20M27.48M-46.30M-45.22M-43.49M-68.90M-42.19M9.65M53.88M89.87M73.96M59.03M-28.08M-162.47M-23.72M
Dividends Paid-5.03M5.12M3.91M7.22M9.70M5.71M1.27M---25.47M42.64M33.48M44.87M56.04M
FCF to OCF4.27%-88.20%85.20%-163.15%-269.62%-87.55%-847.35%-297.18%16.00%52.34%68.38%62.71%44.03%-22.18%-155.79%-21.51%
Dividend Paid to FCF--22.68%18.64%-8.44%-15.98%-22.30%-8.29%-3.01%---34.44%72.24%-119.24%-27.61%-236.22%

Earnings

Report DateMar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Apr 21, 2022Aug 25, 2022Oct 28, 2022Feb 22, 2023Apr 21, 2023
EPS Estimate---------
EPS Actual0.120.090.250.170.150.070.180.090.13
Surprise---------
Timing----Pre-marketAfter-hoursPre-marketPre-marketAfter-hours

Key Statistics & Ratios

Market Cap3.23B
Enterprise Value2.66B
Trailing P/E378.20
Forward P/E0.00
Price / Sales2.63
Price / Book1.87
EPS0.05
Book Value8.39
Revenue (TTM)1.23B
Gross Profit (TTM)861.64M
EBITDA71.78M
Profit Margin0.81%
Operating Margin11.26%
Return on Equity0.42%
Return on Assets0.40%
Shares Outstanding170.94M
Shares Float150.24M
Beta0.49
Dividend Yield1.32%
Dividend Rate0.25
Payout Ratio500.00%

Dividends

20261×
0.25Jun 3, 2026
20251×
0.30Jun 11, 2025
20241×
0.25May 22, 2024
20231×
0.20Jun 29, 2023
20221×
0.25May 27, 2022
20211×
0.15May 27, 2021